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Background: Subspecies B1 human adenoviruses (HAdV-B1) are prevalent respiratory pathogens. Compared to
their species C (HAdV-C) counterparts, relatively little work has been devoted to the characterization of their unique
molecular biology. The early region 3 (E3) transcription unit is an interesting target for future efforts because of its
species-specific diversity in genetic content among adenoviruses. This diversity is particularly significant for the
subset of E3-encoded products that are membrane glycoproteins and may account for the distinct pathobiology
of the different human adenovirus species. In order to understand the role of HAdV-B-specific genes in viral
pathogenesis, we initiated the characterization of unique E3 genes. As a continuation of our efforts to define the
function encoded in the highly polymorphic ORF E3-10.9K and testing the hypothesis that the E3-10.9K protein
orthologs with a hydrophobic domain contribute to the efficient release of viral progeny, we generated HAdV-3
mutant viruses unable to express E3-10.9K ortholog E3-9K and examined their ability to grow, disseminate, and
egress in cell culture.
Results: No differences were observed in the kinetics of infected cell death, and virus progeny release or in the
plaque size and dissemination phenotypes between cells infected with HAdV-3 E3-9K mutants or the parental
virus. The ectopic expression of E3-10.9K orthologs with a hydrophobic domain did not compromise cell viability.
Conclusions: Our data show that despite the remarkable similarities with HAdV-C E3-11.6K, HAdV-B1 ORF E3-10.9K
does not encode a product with a “death-like” biological activity.
Keywords: Adenovirus, E3 region, Genetic polymorphism, Virus egressBackground
Subspecies B1 human adenoviruses (HAdV-B1) are
important causes of acute respiratory disease in children
and military recruits [1–6]. In particular, serotypes 3 and
7 (HAdV-3 and HAdV-7) and their genomic variants are
commonly isolated in association with severe pediatric
acute respiratory disease worldwide [7–10]. Compared
to their species C (HAdV-C) counterparts, relatively lit-
tle work has focused specifically on characterizing the
unique molecular biology of these important human
pathogens. The early region 3 (E3) transcription unit is
of particular interest for its species-specific diversity in* Correspondence: akajon@lrri.org
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reproduction in any medium, provided the orgenetic content among adenoviruses [11,12] and for en-
coding important modulators of the host response to in-
fection [13–16]. This diversity is particularly significant
for the subset of E3-encoded products that are mem-
brane glycoproteins and may account for the distinct
pathobiology of the different human adenovirus species.
Between the highly conserved E3-19K and RIDα, HAdV-
A to -F encode unique repertoires of genes whose pro-
ducts are membrane proteins that belong to the CR1
protein superfamily (pfam02440 in the NCBI CDD) and
that are likely to be responsible for their distinct patho-
biology. Adenovirus CR1 genes are designated CR1α, β,
γ and δ based on their order in the E3 cassette and ex-
hibit some homology with the highly diverse human
cytomegalovirus RL11 gene family [17]. With the excep-
tion of HAdV-C E3-11.6K aka adenovirus death protein
(ADP) and E3-6.7K [18–20] no functional role has beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic of HAdV-3p E3-9K mutant virus genotypes.
Mutant viruses were generated by recombination of bacmid
pKSB2Ad3wt with pE3-9K shuttle plasmids carrying the desired
mutations of ORF E3-9K, digestion of bacmid with MluI to release
the mutated HAdV-3 genome, transfection into A549 cells, and
propagation of resultant mutant virus as described in the Materials
and Methods section. Recombinants contain SalI and BamHI
restriction enzyme sites and a flippase recognition target (FRT) scar
site. The HAdV-3p-WT control virus was generated by linearization of
pKSB2Ad3wt by digestion with MluI without prior recombination or
mutation. HAdV-3p-E-3-9K-rec, the recombination control virus, was
generated by recombination of pKSB2Ad3wt with unaltered pE3-9K
shuttle plasmid. An E3-9K knock out mutant, HAdV-3p-E3-9K-KO, was
generated by recombination of pKSB2Ad3wt with a pE3-9K shuttle
plasmid that contained TAG stop codons in place of all the in-frame
ATG codons present in ORF E3-9K. HAdV-3p-E3-9K-NULL was
generated by recombination of pKSB2Ad3wt with a pE3-9K shuttle
plasmid carrying the HAdV-7h-encoded null version of this ORF
(GenBank accession # Z48954 and AF321310).
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We previously reported the initial characterization of
the uniquely diverse family of orthologs encoded by
HAdV-B1s in ORF E3-10.9K/CR1δ [21,22]. This poly-
morphic HAdV-B1-specific E3 ORF encodes proteins
ranging in predicted size from 4.8 kDa to 10.9 kDa,
depending on the serotype and genomic variant [22].
Our studies showed that orthologs E3-7.7K, E3-9K, and
E3-10.9K containing predicted transmembrane domains
localized to the plasma membrane and to an intracellu-
lar compartment that could not be identified when
expressed ectopically as EGFP-fusion proteins, while the
4.8 kDa ortholog lacking a hydrophobic domain dis-
played diffuse cellular localization [21]. The location of
ORF E3-10.9K in the E3 transcription unit is analogous
to that of HAdV-C E3-11.6K/adenovirus death protein
(ADP) [11]. Like HAdV-C E3-11.6K/ADP, E3-10.9K is
expressed at late time points post-infection from the
adenovirus major late promoter, and exhibits similar
structural features including a hydrophobic domain,
molecular weight, and N- and O-linked glycosylation
[21]. However, the E3-11.6K/ADP primary localization
to the nuclear envelope in infected cells [23] was not
observed for any of the ectopically expressed E3-10.9K
ortholog fusion proteins with a hydrophobic domain
[21]. This led us to hypothesize that HAdV-B1 E3-
10.9Kis a homolog of HAdV-C E3-11.6K/ADP that
facilitates efficient progeny virus release through a differ-
ent mechanism.
In this body of experimental work, we tested this
hypothesis using HAdV-3 mutant viruses lacking the
ability to express ortholog E3-9K and examined their
ability to egress, kill, and disseminate in cultured cells in
comparison with the parental virus.
Results
Generation of HAdV-3-E3-9K knock-out mutants
In order to investigate the role of ORF E3-10.9K in the
growth and progeny release of HAdV-B1s, we generated
HAdV-3p mutant viruses lacking the ability to express a
protein from ORF E3-9K. HAdV-3p encodes a 9 kDa
ortholog in this ORF that is expressed at early times post
infection but also late from a major late promoter tran-
script [21]. Using recombination-based engineering of
the HAdV-3p genome, we generated two control viruses
(HAdV-3p-WT and HAdV-3p-E3-9Krec) and two viruses
unable to express a protein from ORF E3-9K (HAdV-3p-
E3-9K-KO and HAdV-3p-E3-9K-NULL). A schematic
showing the HAdV-3p mutant viruses generated for
these experiments is shown in Figure 1. HAdV-3p-WT
was generated from bacmid pKBS2Ad3wt [24] and had
no alterations to the E3 transcription unit. HAdV-3p-E3-
9K-rec is a recombination control virus containing SalIand BamHI restriction sites flanking ORF E3-9K and a
flippase recognition target (FRT) scar site. Mutant
HAdV-3p-E3-9K-KO was generated by mutating all in-
frame ATG codons in ORF E3-9K to TAG stop codons.
Mutant HAdV-3p-E3-9K-NULL contains the non-coding
version of ORF E3-10.9K encoded in the genome of
HAdV-7h [22,25] and represents a naturally occurring
null mutation in this ORF (Figure 1). The correct genetic
make-up of all viruses was confirmed by sequencing the
relevant portion of E3 region of recombinant viral DNA
and examining the presence of the desired mutations,
the FRT scar site, and intact neighboring ORFs (Genbank
accession numbers JQ278022, JQ278023, and JQ278024).
The absence of expression of ortholog E3-9 K from the
KO and NULL mutants could not be verified due to the
lack of a suitable antibody.
The absence of E3-9K does not alter HAdV-3 cytopathic
effect in infected cells
As an initial assessment of HAdV-3 ORF E3-9K mutant
virus growth phenotype, we examined the cytopathic ef-
fect (CPE) resulting from mutant virus infection of A549
cell monolayers in comparison to the parental and
recombination control viruses. A549 cells were infected
at a MOI of 1 PFU/cell and analyzed by light microscopy
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all viruses. No difference in the progression or appear-
ance of CPE was observed for either HAdV-3p-E3-9K-
KO or HAdV-3p-E3-9K-NULL compared to controls
(Figure 2).
E3-9K mutant viruses do not have a distinct plaque
phenotype compared to the parental virus
In order to investigate whether HAdV-3 E3-9K plays a
role in plaque formation, we examined plaque size
phenotype on A549 cell monolayers infected with our
panel of HAdV-3-E3-9K mutant viruses. Cells were
infected with approximately 20 PFU under a semi-solid
agarose/medium overlay and fixed and stained at 13 days
pi to visualize plaques. No difference in the sizes and
morphology of plaques was observed between control
and mutant HAdV-3 viruses (Figure 3A). In contrast,
and as previously shown, the HAdV-C ADP knock-out
mutant pm734.1 showed distinct differences in plaque
size compared to parental virus rec700 (Figure 3B; [26]).
Interestingly, plaques formed by mutant or WT HAdV-3
viruses exhibited diameters comparable to those formed
by the HAdV-C ADP KO virus.
HAdV-3 mutant viruses lacking E3-9K do not exhibit an
altered viral spread phenotype in cell culture
The ability of HAdV-3-E3-9K mutant viruses to spread
in cell culture was assessed by dissemination assays. In
contrast to a plaque assay, a dissemination assay does
not have a semi-solid agarose/medium overlay. ThisFigure 2 HAdV-3p E3-9K mutant virus-induced cytopathic
effect in A549 cells. A549 cells were infected with HAdV-3 control
viruses (HAdV-3p-WT, HAdV-3p-E3-9K-rec) or HAdV-3p-E3-9K mutant
viruses (HAdV-3p-E3-9K-KO, HAdV-3p-E3-9K-NULL) at a MOI of 1 PFU/
cell and analyzed by light microscopy 4 days pi. Classical adenovirus
CPE was characterized by “webbing” or “lacy” appearance of cells
followed by rounding and detaching of cells from the culture
plate surface.allows virus to freely disperse in the culture medium, in-
stead of being confined to access neighboring cells only.
HAdV-C mutant viruses without E3-11.6K/ADP show a
decreased ability to disseminate in cell culture as com-
pared to HAdV C viruses that do express E3-11.6K/ADP
[27]. A549 cells were infected with HAdV-3p-E3-9K
mutant viruses at MOIs of 1, 0.1, and 0.01 PFU/cell,
replenished with infection medium, and fixed and
stained at 5 days pi to visualize the dissemination of
CPE. No difference was observed among the control
HAdV-3p-WT, the recombination control HAdV-3p-E3-
9K-rec, HAdV-3p-E3-9K-KO, or HAdV-3p-E3-9K-NULL
(Figure 4A). In contrast and consistent with the results
reported by Doronin and colleagues [27], the ADP
knockout mutant pm734.1 showed distinct differences in
dissemination in cell culture when compared to rec700
(Figure 4B).
The lack of E3-9K does not delay viral progeny release
during HAdV-3 infection
Because no differences were found in the cytopathic
effect, dissemination, or plaque size phenotypes of
HAdV-3p-E3-9K-KO or HAdV-3p-E3-9K-NULL com-
pared with control viruses, we next investigated whether
E3-9K played a role in virus progeny egress from
infected A549 cells. Previous work on HAdV-C E3-
11.6K/ADP showed a significant decrease in the progres-
sion of progeny virus egress from cells infected with
mutant viruses lacking the E3-11.6K/ADP [28]. Since we
hypothesized that orthologs of ORF E3-10.9K were likely
the HAdV-B1 homologs of HAdV-C E3-11.6K/ADP, we
carried out a virus egress experiment similar to those
carried out by Tollefson and colleagues [28]. Cells were
infected at a MOI of 10 PFU/cell and extracellular
(supernatant) or total (cells and supernatant) infectious
virus yields were determined by plaque assay. In two
independent experiments, no difference was observed
between the control and mutant viruses in either total
or extracellular infectious virus yields (Figure 5A,B).
However, a control experiment using rec700 and its cor-
responding ADP knock-out mutant pm734.1 showed
obvious differences in the kinetics of virus egress, con-
firming the previously reported role of ADP in facilitat-
ing viral progeny release (Figure 5C,D;[28]).
E3-9K is not involved in progression of host cell death
during HAdV-3 infection
A role in the progression of host cell death has been
reported for HAdV-C E3-11.6K/ADP [26,27]. In order to
determine whether the HAdV-B1 ORF E3-10.9 K/CR1δ
plays a role in cell killing, we used our HAdV-3-E3-9K
mutant viruses to infect A549 cells at an MOI of 10
PFU/cell and examined cell viability by trypan blue
exclusion assay. No difference was observed for the
AB
Figure 3 Growth phenotype of HAdV-3p E3-9K mutant viruses in A549 cell monolayers. A549 cells in 6-well plates were infected with
approximately 20 PFU per well of HAdV-3p E3-9K mutant viruses (A) or HAdV-C rec700 and pm734.1 as a positive control (B) and overlayed with a
semi-solid agarose/medium overlay. At 13 days pi (A) or 6 days pi (B), cells were fixed and stained with crystal violet to visualize plaques.
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pared to control HAdV-3p-WT or recombination con-
trol HAdV-3p-E3-9K-rec (Figure 6). In contrast, ADP
knock out mutant pm734.1-infected cells remained
viable much longer than those infected with the parental
virus control rec700 as originally described by Tollefson
and colleagues [26].
Overexpression of C-term EGFP tagged ORF E3-10.9K
protein orthologs does not result in cell death
To further investigate whether expression of the E3-
10.9K protein orthologs with a transmembrane domain
would compromise cell viability, HeLa TREx cells over-
expressing C-term EGFP fusions of E3-10.9K, and E3-
9K, under tetracycline regulation (described in [21])
were examined at 48 h post induction with tetracycline
using a trypan blue exclusion assay. Prior to trypan blue
staining, cells were examined by bright field and fluores-
cence microscopy to confirm expression of the EGFP1 PFU/cell 
0.1 PFU/cell 
0.01 PFU/cell 
Mock            WT      E3-9K-rec E3-9K-KO A
Figure 4 Dissemination of HAdV-3p E3-9K mutant viruses in A549 cel
cell with HAdV-3p E3-9K mutant viruses (A) or HAdV-C viruses rec700 and p
stained with crystal violet to visualize virus-induced cell monolayer destrucfusion proteins (Additional file 1: Figure S1). No change
in permeability of HeLa TREx cells to trypan blue was
observed, indicating that neither of these proteins by
themselves are able induce cell death (Additional file 2:
Table S1).
Discussion
E3-11.6K/ADP, the only CR1 gene with a known func-
tion encoded in the HAdV-C genome between E3-19K
and RIDα, is expressed at late stages of infection and
facilitates the efficient release of virus progeny at the
end of the virus life-cycle through an unknown mechan-
ism [28]. Because of similarities in location in the E3
transcription unit, molecular weight, expression kinetics
and predicted structural features, we hypothesized that
HAdV-B1 E3-10.9K was a homolog of HAdV-C E3-
11.6K/ADP [21,22]. The results of our experiments
examining growth, dissemination and cell killing pheno-




Mock   rec700  pm734.1 E3-9K-NULL B
l monolayers. A549 cells were infected at a MOI of 1, 0.1, or 0.01 PFU/
m734.1 (B), replenished with liquid medium, fixed at 5 days pi, and
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Figure 5 HAdV-3p E3-9K mutant virus egress from A549 cells. A549 cells were infected with HAdV-3p E3-9K mutant viruses (A-B) or HAdV-C
rec700 and pm734.1 (C-D) at a MOI of 10 PFU/cell, replenished with liquid medium, and total (A,C) or extracellular (B,D) infectious virus yields
were determined by plaque assay at the indicated times pi. A-B is representative of two independent experiments.
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an analogous manner to the well-characterized ADP.
Using our HAdV-3-E3-9 K mutant viruses carrying non-
coding versions of the gene we demonstrated that, in
contrast to the HAdV-Cs used in this study as a refer-
ence for comparison, ortholog E3-9 K does not contrib-
ute to HAdV-3-induced cytopathic effect (Figure 2),
plaque phenotype (Figure 3), dissemination in cell cul-
ture (Figure 4), kinetics of virus progeny release from
infected cells (Figure 5), or host cell death (Figure 6). In
addition, the over-expression as EGFP-fusion proteins of
neither E3-9 K nor the longest ortholog E3-10.9 K
resulted in cell death (Additional file 2: Table S1, Add-
itional file 1: Figure S1). We previously reported that
ORF E3-10.9 K orthologs with a transmembrane domain
ectopically expressed as C-terminus EGFP-fusion pro-
teins did not localize to the nuclear envelope like
HAdV-C E3-11.6 K/ADP. Taken together, these data
support the conclusion that the HAdV-B1 E3-10.9 K
orthologs are not death-like proteins.The lack of information on the functional role of the
diverse repertoire of species-specific E3 membrane pro-
teins remains a major limitation for the understanding
of the molecular bases of the species-specific HAdV
pathobiology. It is extremely likely that adenoviruses of
different species differ in their life strategies and that not
all of them have a need for a lytic/death-like protein at
the end of their life cycle. Although ADP is important
for the efficient release of HAdV-C progeny virions, it is
certainly not essential. Tollefson and colleagues reported
that HAdV-2/5 viruses lacking E3-11.6 K/ADP had a
delayed release of virus progeny, but eventually reached
virus titers equivalent to those of wild-type virus [28].
The need for a lytic protein may be linked to the ability
of the virus to establish latent infections in lymphoid
tissue. To the present, latency in lymphoid tissue has
only been demonstrated for HAdV-C [29–31] but the
role of ADP in reactivation has not been examined.
The genetic determinants and molecular mechanisms
of viral progeny release have not been identified for




















































Figure 6 Viability of HAdV-3p E3-9K mutant virus-infected A549 cells. A. A549 cells were infected with HAdV-3p E3-9K mutant viruses at a
MOI of 10 PFU/cell. Medium and trypsinized cells were pooled at indicated times pi, stained with an equal volume of 0.4% trypan blue solution,
and approximately 200 cells were counted using a light microscope and hemocytometer. The percentage of viable cells was determined by
dividing the number of unstained cells by the total number of cells counted. Error bars indicate standard error of the mean for three
independent experiments. Mock-infected cells were used as a negative control. B. HAdV-C rec700 and pm734.1 controls. Representative trypan
blue exclusion assay results consistent with those reported by Tollefson et al. [26] for the same viruses.
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HAdV-C, other mechanisms of release of progeny
virions have been suggested [32–34]. The evolutionary
advantages/disadvantages of utilizing non-lytic mechan-
isms for viral progeny release have been discussed in the
context of the antibody response from mathematical
modeling of reproductive strategies [35]. It is possible
that HAdVs of different species have evolved unique life
strategies in response to tissue/organ specific host im-
mune responses but the absence of a robust animal
model to study HAdV pathogenesis is still a major limi-
tation for the experimental exploration of this topic.
Interestingly, in cancer animal models, Hemmiki and
colleagues [36] showed that wt HAdV-3 has an oncolytic
activity comparable to that of wt HAdV-5.Conclusions
Our data show that despite the remarkable similarities
with HAdV-C E3-11.6K, HAdV-B1 E3-10.9K does not
encode a product with a “death-like” biological activity.
Recent molecular epidemiology studies have shown that
the most prevalent strains of HAdV-B1 isolated from
cases of acute respiratory disease encode versions of
ORF E3-10.9K that contain truncating or null mutations
[10,37,38] suggesting the existence of a selective advan-
tage for loss of this gene among pathogenic HAdV-B1s.
Interestingly, the genomes of HAdV-B2s appear to
be naturally occurring deletion mutants for this ORF
[39–41]. The investigation of the role of the HAdV-B-
specific E3 CR1 genes, E3-20.1K and E3-20.5K in virus
growth and progeny release is currently in progress in
our laboratory.Like the majority of the E3 genes with a known func-
tion, E3-10.9K may be involved in the modulation of
some aspect of the host response to infection. The pres-
ence of a putative tyrosine sorting motif in the C
terminus of E3-9K and E3-10.9K [21] suggest that these
orthologs may exert their function by exploitation of
intracellular trafficking pathways like the RID complex
proteins [42]. Exploratory work investigating protein
interactions with cellular and/or other viral proteins will
likely be one of the few available options to obtain valu-
able clues to the function and possible mechanism of
action of HAdV-B E3-10.9K and other adenovirus E3-
encoded proteins.Methods
Cells, viruses, media, and growth conditions
A549 cells (ATCC #CCL-185) were grown in 8% (v/v)
newborn calf serum-supplemented Eagle Minimum
Essential Medium (EMEM) (A549 Growth Medium).
HAdV-infected cells were maintained in 2% (v/v) new
born calf serum-supplemented EMEM (A549 Infection
Medium). Plaque assays were overlayed with 2% (v/v)
new born calf serum-supplemented EMEM with 0.7%
(w/v) low melt agarose (A549 Overlay Medium). The
HAdV-C viruses rec700 and pm734.1 were obtained
from Dr. William Wold, Saint Louis University and used
as controls in our experiments. The rec700 virus, an
Ad2-Ad5-Ad2 recombinant [43], was used in our
experiments as the wild type parental virus control.
The pm734.1 virus is an E3-11.6K/ADP knock-out
mutant derived from rec700 [26,28]. Virus stocks for
all experiments described here were grown and their
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cell monolayers.Generation of HAdV-3 mutant viruses
To generate HAdV-3 mutant viruses, we utilized a
recombination-based approach [21]. Briefly, the highly
efficient bacteriophage λRed recombination system [44]
was used to generate HAdV-3 clones encoding two non-
coding versions of ORF E3-9K: HAdV-3-E3-9K-KO
and HAdV-3-E3-9K-NULL. Bacmid pKSB2Ad3wt, which
contains the full-length genome of HAdV-3 prototype
strain GB (HAdV-3p), was a gift from Dr. Silvio Hemmi
[24]. Using the previously described pE3-9K shuttle plas-
mid [21], a series of mutations to ORF E3-9K were intro-
duced. To generate HAdV-3-E3-9K-KO, site-directed
mutagenesis was carried out to change all in-frame Met
codons (ATG) to stop codons (TAG). To generate
HAdV-3-E3-9K-NULL, ORF E3-9K was replaced by the
non-coding version of ORF E3-10.9K encoded by HAdV-
7 h strain Argentina 87–922 [22,25]. The shuttle plas-
mids carrying the desired mutations of ORF E3-9K were
then recombined with pKSB2Ad3wt to generate bacmids
harboring the mutant HAdV-3 genomes. The new bac-
mids were digested with MluI to release the mutated
HAdV genome, and transfected into A549 cells for
mutant virus isolation and propagation as previously
described [21]. Mutant viruses were quality controlled
by sequencing of the portion of the E3 transcription
unit comprising the mutated sites and the flanking ORFs
E3-20.5 K and RIDα (Genbank accession numbers
JQ278022, JQ278023, and JQ278024) and restriction
enzyme analysis of genomic DNA with BamHI and SalI
(data not shown).Virus dissemination assays
A549 cells plated on 24-well culture plates were infected
at a MOI of 1, 0.1, or 0.01 PFU/cell with each virus.
After incubation for 5 days, medium was aspirated and
cells were fixed in 1% formaldehyde and stained with
Accustain crystal violet solution (Sigma-Aldrich, St.
Louis, MO).Virus plaque size assays
A549 cells plated on 6-well culture plates were infected
with approximately 20 PFU of virus per well. After
adsorption for 1 hour at 37°C with periodic rocking to
distribute inoculum, cells were covered with A549 Over-
lay Medium (described above). Plates were incubated for
13 days (HAdV-3 viruses) or 6 days (HAdV-C viruses)
and then fixed in 1% formaldehyde and stained with
Accustain crystal violet solution (Sigma-Aldrich, St.
Louis, MO).Virus egress assays
A549 cells plated on 60 mm dishes were infected at
a MOI of 10 PFU/cell. After adsorption for 1 hour at 37°C,
cells were washed 3 times with PBS to remove
excess extracellular virus. At 6, 12, 24, 36, 48, 72, 96, and
120 h pi, extracellular and total virus samples were har-
vested. In order to collect total virus samples, infected
cells and supernatant were collected and freeze-thawed
3 times at −80°C and room temperature. Samples were
centrifuged at 300 x g for 5 min to remove cellular deb-
ris, and the supernatant was collected. In order to col-
lect extracellular virus samples, the supernatant from
infected cells was collected and transferred to a 5 mL
round-bottomed culture tube. Cells and debris were
removed by centrifugation at 300 x g for 5 min, and the
supernatant was collected. Infectious virus titers in all
samples were determined by plaque assay on A549
cells.
Infected cell viability assays
Infection of A549 cells was carried out in 60 mm dishes
at a MOI of 10 PFU/cell. At 24, 48, 72, 96, and 120 h pi,
medium was collected from samples and transferred to
tubes in order to collect cells already detached from the
monolayer. Adherent cells were trypsinized and pooled
with collected medium. Pooled samples were then mixed
with an equal volume of 0.4% Trypan Blue solution
(Sigma, St. Louis, MO) and approximately 200 cells were
counted using a light microscope and a hemocytometer.
The percentage of viable cells was determined by dividing
the number of unstained cells by the total number of cells
counted and multiplying by 100.
Cell viability of HeLa TREx cells overexpressing ORF
E3-10.9K-EGFP fusion proteins
Previously generated plasmids pcDNA 4/TO EGFP,
pcDNA 4/TO 4.8K-EGFP, pcDNA 4/TO 7.7K-EGFP,
pcDNA 4/TO 9K-EGFP, and pcDNA 4/TO 10.9K-EGFP
[21] were used to transfect low passage HeLa TREx
cells (Invitrogen, Carlsbad, CA) using Effectene Reagent
(Qiagen, Valencia, CA). Cells were maintained under
200 μg/mL Zeocin for two passages to select clones, and
then maintained under 100 μg/mL Zeocin thereafter.
Positive clones with efficient control of fusion protein
expression were identified by their high expression of
EGFP fusion protein upon the addition of 1 μg/mL tetra-
cycline and used in subsequent experiments. To test cell
viability of HeLa TREx cells expressing ORF E3-10.9K-
EGFP orthologous fusion proteins, cells were plated at
approximately 50% confluency in 6-well culture plates.
One day post-plating, medium was aspirated and
replaced with growth medium or growth medium sup-
plemented with 1 μg/mL tetracycline. Medium was then
collected and cells were trypsinized at 48 h post
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http://www.biomedcentral.com/1756-0500/5/429induction. Medium and cells were pooled and stained
with an equal volume of 0.4% Trypan Blue solution
(Sigma, St. Louis, MO). Approximately 200 cells were
counted with a light microscope and a hemocyto-
meter. Percent cell viability was determined by dividing
the number of unstained cells by the total number of
cells counted and multiplying by 100. Expression of
EGFP fusion proteins was confirmed by live-cell fluores-
cence microscopy.
As a positive control for trypan blue staining of non-
viable cells, HeLa TREx cells were plated in 60 mm cul-
ture dishes at approximately 50% confluency and har-
vested by trypsinization 48 h post plating. Cells were
pelleted by centrifugation at 300 x g for 2 min and
resuspended in 1 mL PBS. Three mL of cold (−20°C)
absolute ethanol was slowly added to the cell suspension
while gently mixing and incubated at −20°C for 15 min.
Cells were then pelleted by centrifugation at 300 x g for
2 min and resuspended in 3 mL of PBS. Ethanol-treated
cells were then stained with trypan blue solution and
counted as indicated above.
Additional files
Additional file 1: Figure S1. Viability of HeLa T-REx cells upon
expression of EGFP-tagged ORF E3-10.9K orthologs. HeLa T-REx cells
stably-transfected with pcDNA 4/TO expression plasmids were treated
with 1 μg/mL tetracycline (+Tet) or mock-treated (−Tet). Prior to trypan
blue staining, expression of EGFP-fusion proteins in tetracycline-treated
(+Tet) or untreated (−Tet) live cells was examined by bright field (BF) and
fluorescence (EGFP) microscopy. Images are representative of three
independent experiments.
Additional file 2: Table S1. Viability of HeLa TREx cells expressing ORF
E3-10.9K-EGFP orthologous fusion proteins.
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